Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 96

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 96
---
 and interim periods within fiscal years beginning after December 15, 2024. Retrospective application to all prior periods presented in the financial statements is required for public entities. The Company adopted ASU 2023-07 as of January 1, 2024, which resulted in additional disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

2. ACCOUNTS RECEIVABLE

Accounts receivable were comprised of the following:

|               |     |   |       As 
 of March 
 31, 2025 |     |   |           As 
 of September 
     30, 2024 |
|:--------------|:----|:--|---------:|:----|:--|-------------:|
| Licensee-     
 Related Party |     |   |  149,723 |     |   |       94,873 |
| Total         |     | $ |  149,723 |     | $ |       94,873 |

During the quarter ended March 31, 2025 there was no allowance for doubtful accounts.

<div align='center'>73</div>

3. PREPAID EXPENSES

Prepaid Expenses were comprised of the following:

|          |     |   |       As 
       of 
    March 
 31, 2025 |     |   |        As 
        of 
 September 
   30,2024 |
|:---------|:----|:--|---------:|:----|:--|----------:|
| Prepaid  
 Expenses |     | $ |      265 |     | $ |    42,762 |
| Prepaid  
 Rent     |     |   |        - |     |   |     5,000 |
| Total    |     | $ |      265 |     | $ |    47,762 |

Prepaid expenses consist of payments of certain expenses by cash or issuance of shares for which services are pending to be received.

4. INVESTMENTS

The Company classifies its investment securities as available-for-sale. Available-for-sale securities are recorded at fair value, with unrealized gains and losses reported as a component of other comprehensive income (loss), net of related tax effects, until realized.